Oclacitinib in feline nonflea‐, nonfood‐induced hypersensitivity dermatitis: results of a small prospective pilot study of client‐owned cats

Background Oclacitinib is a Janus kinase (JK)1 inhibitor that has been shown to be effective and safe for the treatment of allergic dermatitis in dogs. Its use in cats has been limited by the absence of pharmacokinetic data. Objective To determine the pharmacokinetic parameters of oclacitinib in cats after oral and intravenous administration. Animals Six adult domestic short hair cats. Methods and materials A two period, two treatment design was used in which cats received oclacitinib maleate i.v. and p.o., at a dose of 0.5 mg/kg and 1 mg/kg, respectively. There was a one‐week interval of washout between the two treatments. Cats received each treatment only once. The plasma concentration of oclacitinib was determined by high‐performance liquid chromatography at 0 min, 5 min, 15 min, 30 min, 1 h, 4 h, 6 h, 10 h and 24 h after intravenous.v administration, at 0 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 10 h and 24 h after p.o. administration. Results After p.o. administration, oclacitinib was absorbed rapidly and almost completely, as shown by an absolute bioavailability of 87% and a Tmax of 35 min. The elimination of the drug also was very rapid as shown by a half‐life of 2.3 h and a clearance calculated as 4.45 mL/min/kg (after i.v. administration). Conclusions and clinical importance The pharmacokinetic parameters of oclacitinib in the cat are similar to those described for the dog, although absorption and elimination are somewhat faster and variability between individuals is somewhat greater. Larger doses and/or shorter dosing intervals would be recommended in cats to achieve similar blood concentrations to those in dogs.

Section: Discussioncontrasting

confidence: 46%

Section: Discussionmentioning

confidence: 67%

A pharmacokinetic study of oclacitinib maleate in six cats

Ferrer

Carrasco

Cristòfol

et al. 2019

“…twice daily for four weeks, in cats affected with NFNFIHD. The hypothesis was that oclacitinib at a higher dose than previously reported would be as effective as oral methylprednisolone in decreasing pruritus and skin lesions in cats with skin allergy …”

Section: Introductionmentioning

confidence: 99%

“…A preliminary open pilot study assessed the efficacy of oclacitinib in cats with allergic dermatitis: cats >12 months of age and 3 kg body weight were treated with oclacitinib, 0.4–0.6 mg/kg (mean dose 0.47 mg/kg) p.o. twice daily for two weeks, then once daily for another two weeks . Oclacitinib was reported to suppress pruritus and clinical signs associated with skin allergy in < 50% of the cats.…”

Section: Introductionmentioning

confidence: 99%

A double‐blinded, randomized, methylprednisolone‐controlled study on the efficacy of oclacitinib in the management of pruritus in cats with nonflea nonfood‐induced hypersensitivity dermatitis

Noli¹,

Matricoti²,

Schievano

2019

Self Cite

Background -Oclacitinib is a Janus-kinase inhibitor that decreases interleukin-31-induced pruritus in cats. At 0.4-0.6 mg/kg/day orally, it decreased pruritus and skin lesions in <50% of allergic cats.Hypothesis/Objectives -To evaluate efficacy and safety of oclacitinib in feline nonflea nonfood-induced hypersensitivity dermatitis (NFNFIHD). Animals -Forty cats with NFNFIHD.Methods and materials -Cats were randomly assigned to receive oclacitinib (group A, 20 cats, 0.7-1.2 mg/kg) or methylprednisolone (group B, 20 cats, 0.5-1 mg/kg) orally twice daily for 28 days. On day (D)1 and D28, lesions were evaluated using the Scoring Feline Allergic Dermatitis (SCORFAD) scale and owners assessed pruritus using a Visual Analog Scale (VAS) and quality of life (QoL) questionnaire. Results were analysed by General Linear Mixed Model (P < 0.05). Haematochemical analyses were performed on D1 and D28.Results -In both groups all parameters improved significantly, with no difference at either time point. Group A had a 61% mean SCORFAD and 54% pruritus VAS improvement, compared with 69% and 67% in group B; 70% of cats in group A and 75% in group B achieved a ≥ 50% reduction of pruritus VAS scores; with 60% and 80% of SCORFAD. There were five non-responders in group A and three in group B. The QoL score improved in both groups (25 and 21%). Four of 14 cats had mild increases in kidney function tests (oclacitinib group) and three of 12 cats had elevated alanine transferase (methylprednisolone group).Conclusions and clinical importance -Oclacitinib appears to be effective for treating pruritus and lesions in cats with NFNFIHD, albeit methylprednisolone seemed to perform better.

“…Oral and injectable glucocorticoids are quite effective but have the potential for severe long‐term adverse effects, including diabetes mellitus . Oclacitinib maleate may be an alternative treatment for cats with allergic skin disease, although in one pilot study only five of 12 (41.6%) cats with nonflea‐ and nonfood‐induced hypersensitivity dermatitis treated with oclacitinib, at the doses recommended for dogs, showed good improvement after 30 days of therapy …”

Section: Introductionmentioning

confidence: 99%

Subcutaneous administration of ciclosporin in 11 allergic cats – a pilot open‐label uncontrolled clinical trial

Koch

Torres

Diaz

et al. 2017